Market Cap: $2.7685T 0.550%
Volume(24h): $89.3211B 31.360%
  • Market Cap: $2.7685T 0.550%
  • Volume(24h): $89.3211B 31.360%
  • Fear & Greed Index:
  • Market Cap: $2.7685T 0.550%
Cryptos
Topics
Cryptospedia
News
CryptosTopics
Videos
Top News
Cryptos
Topics
Cryptospedia
News
CryptosTopics
Videos
bitcoin
bitcoin

$88055.551956 USD

0.66%

ethereum
ethereum

$1577.086174 USD

-3.80%

tether
tether

$1.000050 USD

0.01%

xrp
xrp

$2.082325 USD

-1.64%

bnb
bnb

$598.692215 USD

-0.39%

solana
solana

$139.510407 USD

-0.16%

usd-coin
usd-coin

$0.999860 USD

-0.01%

dogecoin
dogecoin

$0.159973 USD

-0.60%

tron
tron

$0.245980 USD

0.56%

cardano
cardano

$0.622660 USD

-2.38%

chainlink
chainlink

$13.139742 USD

-3.03%

unus-sed-leo
unus-sed-leo

$9.148759 USD

-2.48%

avalanche
avalanche

$19.894905 USD

-0.66%

stellar
stellar

$0.248543 USD

-0.79%

toncoin
toncoin

$2.908279 USD

-3.61%

Cryptocurrency News Articles

GameStop's Bitcoin Bet Sparks Rally Despite Falling Sales

Mar 30, 2025 at 11:30 am

March 30, 2025 – GameStop Corp. (NYSE: GME) made headlines on Wednesday after its shares soared 11.7% despite reporting a 28% year-over-year decline in fourth-quarter net sales.

GameStop's Bitcoin Bet Sparks Rally Despite Falling Sales

GameStop Corp (NYSE:GME) shares soared 11.7% in after-hours trading on Wednesday despite a 28% year-over-year decline in fourth-quarter net sales. The company's board of directors unanimously approved a plan to buy Bitcoin with a portion of its corporate cash reserves, signaling a strategic shift toward cryptocurrency investments.

Later in the session, Dollar Tree Inc (NASDAQ:DLTR) shares rose 3.1% following the release of better-than-expected fourth-quarter earnings, while Humacyte Inc (NASDAQ:HUMA) stock surged after announcing successful results from a clinical trial for its bioengineered blood vessels.

Tech giants Nvidia (NASDAQ:NVDA) and Tesla (NASDAQ:TSLA) pulled back after the bell, as a broader sell-off in the technology sector unfolded, driven by concerns over regulatory challenges in China.

Scroll down to continue reading.

GameStop Surprises With Bitcoin Plans Amid Weak Sales

GameStop reported fourth-quarter earnings that painted a mixed picture. While the company's decision to add Bitcoin to its balance sheet surprised investors, the core retail business showed signs of weakness.

The company's net sales fell by 28% year-over-year to $2.1 billion, missing the analysts' estimates of $2.21 billion. The gross profit margin narrowed by 210 basis points to 24.3%, and operating expenses increased by 11%.

On a positive note, GameStop managed to beat the earnings per share expectations, reporting a loss of $0.61 per share, compared to the analysts' estimates of $0.68 loss per share.

Furthermore, the company's board of directors resolved to allocate a portion of the company's cash reserves to purchase Bitcoin, in addition to other digital currency wallet technologies. This move signals a new chapter for GameStop, which has been struggling to adapt to the changing retail landscape.

Dollar Tree Edges Up 3.1% on Beating Earnings

Shares of Dollar Tree rose slightly in after-hours trading on Wednesday after the discount retailer reported better-than-expected fourth-quarter earnings and announced plans to sell its Family Dollar stores.

For the quarter, Dollar Tree reported earnings per share of $1.54, beating the average analyst estimate of $1.41 per share, according to Benzinga. The company also reported revenue of $8.04 billion, compared to the average estimate of $7.96 billion.

The discount retailer also announced that its board of directors had authorized a new share repurchase program of up to $2 billion of common stock.

Humacyte Shares Soar on Positive Clinical Trial Results

Humacyte shares skyrocketed in after-hours trading on Wednesday after the company announced that it had received positive top-line results from a pivotal clinical trial of its bioengineered blood vessels.

The company said that the trial, which was conducted by the U.S. Food and Drug Administration, met its primary endpoint of showing a statistically significant improvement in the rate of occlusion-free primary endpoints at six months in patients treated with Humacyte's products, compared to the standard of care.

The trial also met all of its secondary endpoints, including a significant reduction in the risk of major adverse events and a rapid return to normal daily activity in patients treated with Humacyte's products.

"These top-line data from the pivotal U.S. FDA trial represent a significant milestone in Humacyte's journey to develop and bring to market best-in-class cellular therapies for patients in critical need," said Humacyte CEO, Robert L. Cohen.

Tech Sector Sells Off as Nvidia, Tesla Shares Decline

In after-hours trading on Wednesday, shares of Nvidia pulled back slightly after the company reported better-than-expected fourth-quarter earnings and announced plans to lay off workers.

For the quarter, Nvidia reported earnings per share of $0.32, compared to the average analyst estimate of $0.27 per share, according to Benzinga. The company also reported revenue of $6.03 billion, compared to the average estimate of $5.9 billion.

Later in the session, Tesla shares fell in after-hours trading following a report from China's Xinhua news agency.

According to the report, the China Banking and Insurance Regulatory Commission and other regulators met with representatives of major U.S. investment institutions earlier this month to discuss cooperation and address concerns raised by the institutions regarding the business environment in China's capital markets.

The U.S. institutions expressed worries about the stability of the Chinese stock market and suggested that the country could learn from the U.S. experience in terms of securities law enforcement and investor protection.

The report comes amid heightened tensions between the U.S. and China, particularly in the technology sector.

GameStop's Bitcoin move and struggles

The company's

Disclaimer:info@kdj.com

The information provided is not trading advice. kdj.com does not assume any responsibility for any investments made based on the information provided in this article. Cryptocurrencies are highly volatile and it is highly recommended that you invest with caution after thorough research!

If you believe that the content used on this website infringes your copyright, please contact us immediately (info@kdj.com) and we will delete it promptly.

Other articles published on Apr 22, 2025